CN112870332A - A tablet containing lysozyme for treating fatty liver - Google Patents
A tablet containing lysozyme for treating fatty liver Download PDFInfo
- Publication number
- CN112870332A CN112870332A CN202110389703.8A CN202110389703A CN112870332A CN 112870332 A CN112870332 A CN 112870332A CN 202110389703 A CN202110389703 A CN 202110389703A CN 112870332 A CN112870332 A CN 112870332A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- glutathione
- salvianolic acid
- liver
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 31
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 31
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 30
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 30
- 102000016943 Muramidase Human genes 0.000 title description 2
- 108010014251 Muramidase Proteins 0.000 title description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title description 2
- 229960000274 lysozyme Drugs 0.000 title description 2
- 239000004325 lysozyme Substances 0.000 title description 2
- 235000010335 lysozyme Nutrition 0.000 title description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 140
- 229960003180 glutathione Drugs 0.000 claims abstract description 67
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims abstract description 50
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims abstract description 50
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims abstract description 50
- 108010024636 Glutathione Proteins 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 47
- 238000002360 preparation method Methods 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000009044 synergistic interaction Effects 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 150000003254 radicals Chemical class 0.000 description 21
- 239000001301 oxygen Substances 0.000 description 20
- 229910052760 oxygen Inorganic materials 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 230000006378 damage Effects 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 239000003925 fat Substances 0.000 description 14
- 208000031225 myocardial ischemia Diseases 0.000 description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 210000005229 liver cell Anatomy 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000003859 lipid peroxidation Effects 0.000 description 9
- 230000003908 liver function Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 7
- -1 oxygen radicals Chemical class 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000034935 Familial LCAT deficiency Diseases 0.000 description 6
- 208000026516 Norum disease Diseases 0.000 description 6
- 206010063837 Reperfusion injury Diseases 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 6
- 229930183842 salvianolic acid Natural products 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- 206010019668 Hepatic fibrosis Diseases 0.000 description 5
- 102000004890 Interleukin-8 Human genes 0.000 description 5
- 108090001007 Interleukin-8 Proteins 0.000 description 5
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 5
- 229940096397 interleukin-8 Drugs 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 4
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 244000132619 red sage Species 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- 241000620196 Arthrospira maxima Species 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 240000007164 Salvia officinalis Species 0.000 description 3
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 3
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000001964 calcium overload Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 102000023984 PPAR alpha Human genes 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 206010046337 Urate nephropathy Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 235000014590 basal diet Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 210000004024 hepatic stellate cell Anatomy 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000005399 mechanical ventilation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000008065 myocardial cell damage Effects 0.000 description 2
- 208000037891 myocardial injury Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 2
- 150000007965 phenolic acids Chemical group 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229930189533 tanshinol Natural products 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 108010080705 Ca(2+) Mg(2+)-ATPase Proteins 0.000 description 1
- 208000026889 Cell metabolism disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108010001202 Cytochrome P-450 CYP2E1 Proteins 0.000 description 1
- 102100024889 Cytochrome P450 2E1 Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 244000052909 Dioscorea esculenta Species 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930189936 Glyoxalase Natural products 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 208000011948 Multi-organ disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 208000032026 No-Reflow Phenomenon Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 208000033774 Ventricular Remodeling Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000010350 chaihu-shugan-san Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 230000023143 endothelial cell-cell adhesion Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 210000003111 iliac vein Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- SCOAVUHOIJMIBW-UHFFFAOYSA-N phenanthrene-1,2-dione Chemical class C1=CC=C2C(C=CC(C3=O)=O)=C3C=CC2=C1 SCOAVUHOIJMIBW-UHFFFAOYSA-N 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000009696 ping wei san Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 150000003641 trioses Chemical class 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating fatty liver, wherein the weight ratio of active ingredients of glutathione to salvianolic acid B is (1:20) - (20: 1). Compared with western medicine preparations, the pharmaceutical composition provided by the invention is simple in preparation method and reasonable in compatibility, and the two active ingredients can generate a synergistic interaction effect while exerting respective effects, so that the fatty liver is remarkably treated. Wherein the glutathione and the salvianolic acid B are natural in source, safe and nontoxic and have no side effect; the medicine composition has no western medicine component, so that the medicine has no drug resistance.
Description
Technical Field
The invention relates to the field of medicines, and in particular relates to a medicinal composition for treating fatty liver.
Background
Fatty liver is a fatty liver caused by various diseases and causes, and epidemiologically researched chronic fatty liver mainly caused by alcohol, obesity and the like. Fatty Liver (FLD) is classified broadly into Alcoholic Fatty Liver (AFLD) and non-alcoholic fatty liver (NAFLD) or both clinically according to the presence or absence of excessive drinking history of a patient. AFLD refers to fatty liver caused by long-term drinking. NAFLD refers to a condition that is caused by, in addition to alcohol and other well-defined liver damage factors, including simple fatty liver, steatohepatitis (NASH), and NASH-associated cirrhosis. The incidence of FLD in China is increasing day by day, and FLD is becoming one of the most common chronic liver diseases in China and seriously harms the health of people.
Toxic metabolites produced by the metabolism of ethanol in liver cells and the resulting metabolic disorders are the main causes of alcoholic liver injury. Acetaldehyde, a metabolite of ethanol, is hepatotoxic and contributes to liver fat accumulation by impairing the function of peroxisome proliferator-activated receptor alpha (PPAR- α) and increasing the expression of sterol regulatory element binding protein-1 (SREBP-1). When the level of fatty acids is increased, PPAR- α is activated, inducing an increase in synthesis of fatty acid metabolizing enzymes, and regulating fatty acids to normal levels. Under the induction of acetaldehyde, PPAR-alpha function is reduced, SREBP-1 expression is enhanced, enzyme synthesis related to fat metabolism is reduced, enzyme expression related to fat synthesis is increased, and fat synthesis is increased. Endotoxemia caused by ethanol is possibly related to the pathogenesis of alcoholic fatty liver, and Endotoxin (ET) can stimulate hepatomegaphagy cells (KC) to release cytokines such as tumor necrosis factor (TNF-alpha) and interleukin-8 (IL-8) and inflammatory mediators. TNF-alpha is combined with TNF-alpha receptor on cell membrane to increase the formation of active oxygen in liver and induce liver cell apoptosis. IL-8 is an inflammatory chemokine, which causes neutrophils to accumulate at inflammatory sites, exacerbating hepatocyte injury. The damage of TNF-alpha and IL-8 to the liver may be one of the important mechanisms for the occurrence of AFLD.
The pathogenesis of NAFLD is a complex "secondary hit" theory that is recognized by most scholars, where the primary hit is mainly Insulin Resistance (IR), which causes hepatic cell steatosis by promoting peripheral lipolysis and hyperinsulinemia and initiates cell adaptation programs, while the relative lack of viability of the steatosis hepatic cells provides sufficient reaction matrix for oxygen stress, resulting in increased sensitivity of the steatosis hepatic cells to internal and external damaging factors; the secondary hit is mainly caused by the increase of reactive oxidative metabolites, so that lipid peroxidation is induced and activated by the cytokine, the mitochondrial uncoupling protein 2 and the fas ligand, and further, the inflammation, necrosis and even fibrosis of the fatty degeneration liver cells are caused. Reactive Oxygen Species (ROS) are considered to be the most important factor for the development of NAFLD. ROS are generated in one stroke, and in the second stroke, in addition to fibrosis of liver tissues caused by regulation of mitochondrial membrane permeability, induction of apoptosis and generation of a series of cytokines and inflammatory adhesion factors, unsaturated fatty acids can be attacked by self to generate a large amount of peroxidation products, Hepatic Stellate Cells (HSC) are activated under the action of genetic hemochromatosis gene mutation, a renin-angiotensin-aldosterone system and leptin, autoimmunity is induced, the oxidation resistance of an organism is reduced, a large amount of ROS are continuously generated, severe vicious circle is caused, and the development of hepatic fibrosis is promoted.
At present, the medicines for treating fatty liver mainly take western medicines, which can be divided into several types according to the action mechanism:
(1) insulin sensitizer: the abnormality of lipid metabolism caused by insulin resistance is the first hit in the formation of FLD. Insulin sensitizers may therefore be an effective method of treating FLD. A biguanide: the representative medicine is metformin, which can obviously enhance the sensitivity of peripheral tissues to insulin and has certain functions of reducing weight and reducing hyperinsulinemia. Thiazolidinediones: reduce the release of free fatty acids and tumor necrosis factor from adipocytes, increase glucose utilization, while increasing insulin sensitivity, inhibiting lipid peroxidation and TNF- α activity, and enabling selective transfer of fat from the gut to the subcutaneous tissue.
(2) Lipid-lowering drugs: gemfibrozil: has effects in promoting fatty acid uptake, transport, oxidation and utilization of liver, and maintaining lipid balance in cell. ② clofibrate: mainly through inhibiting adenylate cyclase, cAMP content in fat cells is reduced, fat tissue hydrolysis is inhibited, non-acetified fatty acid content in blood is reduced, so that Very Low Density Lipoprotein (VLDL) synthesis and secretion of liver are reduced, lipoprotein lipase activity is enhanced, decomposition and metabolism of VLDL and Triglyceride (TG) are accelerated, and contents of blood Low Density Lipoprotein (LDL), TG, low density lipoprotein cholesterol (LDL-C) and Total Cholesterol (TC) are reduced. ③ orlistat: orlistat is a potent inhibitor of pancreatic lipase, an important enzyme in the small intestine that hydrolyzes food fat and facilitates fat absorption (as monoglycerides). Studies have demonstrated that inhibition of lipase activity can limit the absorption of dietary triacylglycerols, thereby inhibiting the intake of exogenous fat. Fourthly, elastase: the elastase-elastase inhibitor is a balance system in normal human blood, and can regulate the balance of the system, prevent the synthesis of cholesterol, promote the conversion of cholesterol into bile acid, accelerate the excretion of bile, reduce the contents of TG and TC in blood, increase the level of high density lipoprotein cholesterol (HDL-C), and reduce fat transported to liver by supplementing elastase.
(3) Antioxidant: vitamin E, betaine, spirulina maxima, etc.: oxygen stress and lipid peroxidation play an important role as secondary attacks in the formation of NASH, and blocking oxygen stress and lipid peroxidation may have a therapeutic effect on NASH, and thus antioxidants may become an effective method for treating NASH. Vitamin E has a certain antioxidant effect, but it should be noted that long-term massive vitamin E supplementation can also increase mortality. When the patient suffering from NAFLD is treated by the spirulina maxima, the B-ultrasonic and biochemical examination finds that the spirulina maxima really has good treatment effect on the patient suffering from NAFLD and can be used as an auxiliary treatment medicine for NAFLD.
(4) Cytochrome P450Inhibitor (B): cimetidine is H2Receptor antagonists and also cytochrome P450And (3) an inhibitor. Experiments prove that cimetidine can inhibit NAFLD rat liver microsome CYP450And isoenzyme CYP2E1, reducing Hyaluronic Acid (HA) content in serum, and improving liver function, thereby relieving NAFLD liver tissue inflammation. (5) And (3) probiotics: the probiotics have the function of regulating intestinal flora interfering with the intestinal and hepatic axis. Data of 4 liver disease research centers are searched, and results only include preliminary data of 2 non-random experimental researches, which suggest that probiotics have better tolerance, can improve conventional liver function indexes and reduce lipid peroxidation markers. But the lack of randomized clinical trials has not made the possibility to support or refute probiotics for NAFLD or NASH. The normal intestinal flora has an important therapeutic effect on hyperlipidemia.
According to traditional Chinese medicine, FLD is caused by overeating fat, sweet and thick taste, obesity, excessive drinking, emotional disorder, or feeling of damp-heat and epidemic toxicity, or body deficiency due to long-term illness, food stagnation, qi stagnation, epidemic qi and the like, so that liver dysfunction, spleen dysfunction, endogenous damp evil, phlegm stagnation, kidney essence deficiency, phlegm stagnation and the like are caused. Modified chaihu Shugan san for liver qi stagnation, modified Pingwei san for phlegm-dampness stagnancy in spleen, modified chaihu Tang for damp-heat retention, modified Fuyuan Huoxue Tang for blood stasis obstruction of collaterals, and modified water-nourishing and liver-clearing decoction for yin deficiency and liver qi stagnation. Eight acupuncture points (moisture, Yinjiao, Tinsmen, Wailing, Tianshu, Ganshu, Qimen, Zusanli, Fenglong, Quchi and Sanyinjiao) around the umbilicus are selected for treating obesity FLD32 cases, a reinforcing and reducing method of lifting, inserting and twirling is applied, and a continuous wave of electric needles is added, so that the patients can tolerate the acupuncture for 30min, 1 time every other day, 12 times of treatment are 1 treatment course, and generally 2-3 treatment courses are adopted. As a result, 18 cases were clinically cured, 8 cases were significantly effective, 4 cases were effective, and 2 cases were ineffective. 28 patients with NAFLD were randomized into 2 groups. 12 control groups are subjected to basic liver protection treatment, and 16 treatment groups are orally taken liver strengthening capsules on the basis of the control groups. Clinical symptoms, liver function, serum hepatic fibrosis index, oxidative stress index and biopsy liver pathological change condition of the patient are observed before and after 6 months of treatment. The results show that all indexes are obviously improved, and the comparative difference between the treatment group and the control group after treatment has statistical significance (P is less than 0.05). The liver strengthening capsule can improve liver inflammation, promote fat metabolism in liver, protect liver cell and reverse hepatic fibrosis.
In common medicines for treating fatty liver, western medicines have obvious curative effect but are easy to generate drug resistance after long-term administration, and a traditional Chinese medicine compound has limited treatment effect although low toxicity and no drug resistance, so that researchers focus on the research of fatty liver treatment on natural-source medicines, and glutathione and natural traditional Chinese medicine products are particularly attracted.
Glutathione is a peptide naturally synthesized in human cells, consisting of glutamic acid, cysteine and glycine, and is present throughout animal tissue cells. Glutathione exists in vivo in both reduced (GSH) and oxidized (GSSG) forms. Reduced Glutathione (GSH) is the predominant active state, accounting for approximately 95%; oxidized glutathione (GSSG) is inactive, accounting for about 1%. It has been studied that the thiol group (-SH) contained in GSH is a group that plays a major role, and plays a role in the activation of enzymes and the scavenging of free radicals in the human body. When human tissue cells are aged, infected, poisoned and subjected to oxidative stress, the biosynthesis capability of GSH in the cells can be reduced and the content of the GSH is reduced. The timely supplement of exogenous GSH can prevent, alleviate and stop the damage of tissue cells and change the pathophysiological process.
GSH, an important intracellular metabolite that regulates, is a prosthetic group of glyceraldehyde phosphate dehydrogenase and a coenzyme of glyoxalase and triose dehydrogenase, participates in the tricarboxylic acid cycle and sugar metabolism in vivo, and activates various enzymes such as thiol (SH) enzyme-coenzyme, thereby promoting the metabolism of sugars, fats and proteins. GSH molecule is characterized by active sulfydryl (-SH), which is the most important functional group, can participate in a plurality of important biochemical reactions of organisms, protects important enzyme protein sulfydryl in vivo from oxidation and inactivation, and ensures energy metabolism and cell utilization. Meanwhile, the sulfhydryl is combined with free radicals in vivo, so that the free radicals can be directly reduced into acidic substances, the excretion of the free radicals is accelerated, and the damage of the free radicals to important organs is resisted. GSH has been found to be involved in regulation of lipopolysaccharide-induced cytokine transcription and regulation of the I-KB/NF-KB signaling pathway. Studies have also found that a reduction in GSH levels is a potential early activation signal for apoptosis, with subsequent generation of oxygen radicals that contribute to apoptosis.
GSH is used as an important metabolic regulation agent and antioxidant in cells, has the functions of removing oxygen free radicals, enhancing the activity of antioxidant enzyme, improving the antioxidant defense capacity of organisms and the like, becomes a medicine for consistent treatment and adjuvant therapy of various diseases, and is widely applied to liver damage, kidney damage, lung diseases, eye diseases, cardiovascular and cerebrovascular diseases, multi-system and multi-organ diseases such as Parkinson and the like at present. It has also been reported that GSH has the function of inhibiting AIDS. With the continuous and intensive research, the application range can be further expanded.
GSH as an auxiliary drug has good effect on treatment of liver diseases, and according to research, when liver cells are damaged, GSH in the cells can be exhausted or reduced in synthesis, various oxidation free radicals are increased, when the concentration of the GSH in vivo is lower than a critical value, various GSH dependent enzyme systems are inactivated, the protection on the oxidation free radicals is weakened, the free radicals cause damage to liver cell membranes and the like through lipid peroxidation of biological membranes, and directly cause the activity change of liver cell mercaptoenzymes to cause the degeneration and the necrosis of the liver cells. The exogenous GSH can provide reducing agent for GSH oxidase, recover activity of GSH enzyme system, inhibit or reduce free radical generation, block damage of oxygen free radical to liver cell, and accelerate excretion of free radical to protect liver cell.
When treating acute viral hepatitis patients, after GSH is given to a treatment group, the liver function detection index and the effective rate of the patients in an observation group are obviously superior to those of a control group, and the patients have less adverse reaction during medication, and are safe and reliable. When the effect of GSH on alcoholic liver disease is observed, the treatment group is treated by GSH on the basis of conventional treatment. The results showed that both groups improved liver function to different extents, but the treated group was superior to the control group (P < 0.05). When the clinical curative effect of alcoholic cirrhosis is observed, GSH is added to the treatment group for treatment. The clinical curative effect of the result observation group and the index for reducing liver function and hepatic fibrosis are obviously superior to those of the control group, which shows that the effect of reducing glutathione for treating alcoholic cirrhosis is good, hepatic fibrosis can be obviously inhibited, and liver function can be improved.
Gouty nephropathy is caused by long-term hyperuricemia, and inhibits the production of renal NO. The research suggests that GSH can stabilize the function of endothelial cells by removing free radicals, antagonize the inhibition effect of hyperuricemia on kidney NO, and reduce the damage to renal tubules and interstitium and the toxicity of medicaments on kidney. For the treatment of gouty nephropathy patients, 18 patients were observed with GSH. As a result, the observation group showed 7 cases (38.9%) of significant effect, 14 cases (77.8%) of total significant effect, the control group showed 3 cases (16.7%) of comparative significant effect, and 10 cases (55.6%) of total significant effect. The observation group is obviously superior to the control group in the aspects of reduction of blood creatinine, reduction of urine protein, improvement of renal function and the like (P is less than 0.05), and no adverse reaction is found.
The action mechanism of GSH for treating lung diseases is not clear at present, and researches suggest that GSH can completely eliminate oxygen free radicals, hydrogen peroxide and hydrogen free radicals, and can also derive various oxides with peroxidase produced by leukocytes in an oxygen stress state, so that GSH has a certain inhibition effect on further participating in oxygen free radical generation reaction in organisms. Patients with chronic obstructive pulmonary disease are treated with a combination of mechanical ventilation and GSH, and the combination is treated with a combination of mechanical ventilation and GSH. Results the symptom control effect (total effective rate 93.3%) of the patients in the combined group is obviously better than that of the patients in the ventilation group (total effective rate 75.5%), the ventilation treatment time and the hospitalization time are obviously shorter than those of the patients in the ventilation group (P <0.05), and no adverse reaction occurs in the treatment period of the patients in the two groups. In the treatment of patients with severe pneumonia, the observation group received conventional treatment and was treated with GSH for adjuvant treatment. The results show that the total effective rate (77.78%) of the observed patients is obviously higher than that of the control group (66.67%), and simultaneously, each physical index of the observed patients after treatment is also better than that of the control group (P < 0.05).
GSH has protective effect on chemotherapy patients, and when tumor patients receive chemotherapy for a long time, a large amount of oxygen free radicals and other active oxygen free radicals are generated in the organism, so that peroxidation damage is caused to organism tissues, liver function is seriously affected, and immunity reduction, cell metabolism disorder, DNA damage, protein damage, cell damage and death can be caused when the disease condition is serious. GSH can remove oxygen radicals, has detoxifying effect, and effectively protects normal function of liver cells in organism. When the influence of GSH on the damage of bone marrow function and liver function caused by chemotherapy of tumor patients is researched, the indexes of white blood cell amount, glutamic-pyruvic transaminase and the like are better in the treatment group than the control group after the GSH is added in the prevention group.
Salvia miltiorrhiza, which is the dried root and rhizome of Salvia miltiorrhiza (Salvia millirrhiza Bunge) belonging to Salvia of Labiatae, was recorded in Shennong Ben Cao Jing, the ancient herbal thereof. The salvia miltiorrhiza, which is slightly cold in property and bitter in taste, has no toxicity and has the effects of removing blood stasis, relieving pain, promoting blood circulation, regulating menstruation, nourishing heart and relieving restlessness. The red sage root is widely used for treating cardiovascular system diseases clinically, and has the functions of dilating coronary artery, increasing coronary blood flow, improving microcirculation, reducing myocardial oxygen consumption, preventing and treating myocardial ischemia and myocardial infarction, etc.
The main chemical components of Saviae Miltiorrhizae radix include water soluble phenolic acid compounds represented by salvianolic acid B and alcohol soluble phenanthrenequinone compounds represented by tanshinone IIA. The water-soluble components of Saviae Miltiorrhizae radix have phenolic acid structure, wherein tanshinol has basic chemical structure of various salvianolic acids. A series of phenolic acids found hereafter are named salvianolic acid (salvianolic acid). The salvianolic acid B is prepared by condensing 3 molecules of tanshinol and one molecule of caffeic acid. The content of salvianolic acid B in the medicinal materials can reach 2% -8%, which is the most main active component in the water-soluble components of the salvia miltiorrhiza, and the content of salvianolic acid B in the total salvianolic acids is the highest, and accounts for about 70%. Salvianolic acid B is weakly acidic, is easily soluble in water, alcohol, ethyl acetate and other solvents, and is mainly extracted by water, ethanol or ethyl acetate at present. Salvianolic acid B has effects of resisting myocardial ischemia, resisting oxidation, resisting coagulation, resisting thrombi, regulating blood lipid, increasing coronary artery flow, improving heart function, and resisting inflammation.
The salvianolic acid compounds have strong antioxidation, and in vivo and in vitro experiments prove that the salvianolic acid can clear oxygen free radicals and inhibit lipid peroxidation. Research shows that the salvianolic acid B can eliminate active oxygen in cells and improve the oxidation resistance of the whole cells by improving the activities of superoxide dismutase (SOD), Catalase (CAT) and Glutathione Peroxidase (GPX), has higher action strength of eliminating oxygen free radicals and inhibiting lipid peroxidation than vitamin C and vitamin E, and is one of the currently known natural products with the strongest oxidation resistance.
Salvianolic acid B inhibits AS production in hypercholesterolemic animals, and is not only related to its cholesterol-lowering effect, but also because its antioxidant effect prevents endothelial damage and prevents oxidative modification of LDL. The intravenous injection of salvianolic acid B can reduce myocardial ischemia degree of coronary artery ligation dog and reduce myocardial ischemia range, and the action intensity is dose-dependent. The action mechanism of the medicine is probably to improve the SOD content in cells, reduce the toxic action of free radicals on myocardial cells, and effectively promote the proliferation of fibroblasts in infarct foci, thereby accelerating the repair process of the heart. Myocardial ischemia reperfusion injury can generate a large amount of oxygen free radicals, which cause lipid peroxidation of myocardial cell membranes, thereby causing aggravation of myocardial injury. Salvianolic acid B can relieve ischemia reperfusion injury by increasing SOD activity, inhibiting oxygen free radical injury to myocardium.
Ca2+Overloading contributes to the formation of oxygen radicals, leading to reperfusion injury. The study showed that intracellular Ca2+-Mg2 +Decreased ATPase (calcium magnesium ATPase) activity, possibly leading to intracellular calcium overload, while salvianolic acid B on Ca in myocardial ischemia cells2 +-Mg2+The decrease of ATPase activity has better antagonism, thereby reducing the intracellular calcium overload during myocardial ischemia. Calcium overload test of simulating myocardial ischemia reperfusion injury by culturing myocardial cells in vitro proves that salvianolic acid B can obviously reduce intracellular Ca2+The concentration of (c). The research shows that the salvianolic acid B has a better protective effect on the myocardial of a rat with acute myocardial ischemia reperfusion injury.
The salvianolic acid has a strong effect of resisting vascular endothelial cell injury caused by oxidative stress. Salvianolic acid B can promote the synthesis of Nitric Oxide (NO) of endothelial cells, scavenge Reactive Oxygen Species (ROS) in cells, and regulate the action relationship between NO and ROS. The action mechanism of the salvianolic acid B for protecting heart microvascular endothelial cells (CMEC) and resisting myocardial hypoxia injury comprises the following aspects: phi is involved in the synthesis of stress-induced heat shock protein 70(HSP 70). Secondly, the endogenous delayed protection mechanism of CMEC can be activated, the cell survival rate and the SOD activity are improved, the levels of Lactate Dehydrogenase (LDH) and NO are reduced, and the myocardial ischemia and hypoxia injury effect is antagonized. And the inhibitor has obvious inhibition effect on vascular endothelial permeability increase induced by Vascular Endothelial Growth Factor (VEGF). And fourthly, the activity increase of matrix metalloproteinase-2 (MMP-2) caused by Lysophosphatidylcholine (LPC) is obviously inhibited, and the protective effect on the cardiovascular system damage mediated by LPC is possibly realized. Inhibit the permeability increase of endothelial cells caused by tumor necrosis factor-alpha (TNF-alpha), and has direct protection effect on the injured rat microvascular endothelial cells.
The salvianolic acid B can be administered by intravenous injection to reduce myocardial ischemia degree, reduce myocardial ischemia range, and relieve myocardial cell injury, and has therapeutic effect on myocardial infarction; can increase coronary blood flow, reduce oxygen uptake rate of myocardium, and protect heart. Salvianolic acid B preconditioning and O deficiency2The pre-adaptation hasSimilar cytoprotective effect can enhance the subsequent O deficiency of cells for a longer time2O complex2Tolerance of the injury, thereby activating the cellular endogenous protective mechanisms.
Under normal physiological conditions, plasma thromboxane A2Prostacyclin (TXA)2/PGI2) The proportion is relatively balanced to keep the internal environment of the body stable. The research finds that the salvianolic acid B can reduce the release of Endothelin (ET) and improve TXA2/PGI2Systemic imbalance, reducing myocardial cell damage; and can improve TXA during ischemia reperfusion2/PGI2The strong constriction of the microvessels, the formation and blockage of thrombus in the microvessels caused by serious unbalance, and the no-reflow phenomenon is restrained. The interaction between the free radical reaction and the arachidonic acid metabolite is probably participated in the formation mechanism of the myocardial ischemia reperfusion without the phenomenon of reflow together.
Salvianolic acid B can reduce leukocyte infiltration by reducing expression of endothelial cell-cell adhesion factor (ICAM-1), thereby relieving myocardial injury. Salvianolic acid B can regulate the release of inflammatory factors during myocardial ischemia, inhibit the transcription and translation of c-fos, IL-1 beta, IL-6 and IL-8, and is one of the mechanisms for improving ventricular remodeling after myocardial infarction and promoting myocardial tissue repair.
At present, the application of the combination of glutathione and salvianolic acid B in the treatment of fatty liver is not reported.
Disclosure of Invention
The invention aims to solve the technical problem of providing a pharmaceutical composition which can effectively treat fatty liver, has no toxic or side effect and drug resistance and has natural active ingredients.
The technical scheme adopted by the invention for solving the problems is to provide the pharmaceutical composition for treating the fatty liver, wherein the weight ratio of the active ingredients of glutathione to salvianolic acid B is (1:20) - (20: 1).
Preferably, the weight ratio of the active ingredients of the glutathione to the salvianolic acid B is (1:9) - (9: 1).
More preferably, the weight ratio of the active ingredients of the glutathione to the salvianolic acid B is 4: 1.
Preferably, the glutathione is reduced glutathione.
Preferably, the pharmaceutical composition further comprises pharmaceutically acceptable auxiliary materials.
More preferably, the pharmaceutically acceptable auxiliary materials are selected from one or more of starch, microcrystalline cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, magnesium stearate and aerosil.
Preferably, the dosage form of the pharmaceutical composition is tablets, capsules, injection powder, dripping pills and the like, and more preferably tablets.
Preferably, the pharmaceutical composition comprises 1-10 parts by weight of glutathione and salvianolic acid B in 100 parts by weight of the pharmaceutical composition.
The invention also provides application of the pharmaceutical composition in preparing a medicament for treating fatty liver.
Preferably, the fatty liver is non-alcoholic fatty liver.
The invention has the positive and beneficial effects that:
surprisingly, through repeated experiments, the invention unexpectedly discovers that the combination of the glutathione and the salvianolic acid B has a synergistic effect on the prevention and treatment of the fatty liver, and the effect is better when the combination of the glutathione and the salvianolic acid B is matched with other active ingredients. Compared with western medicine preparations, the pharmaceutical composition provided by the invention is simple in preparation method and reasonable in compatibility, and the two active ingredients can generate a synergistic interaction effect while exerting respective effects, so that the fatty liver is remarkably treated. Wherein the glutathione and the salvianolic acid B are natural in source, safe and nontoxic and have no side effect; the medicine composition has no western medicine component, so that the medicine has no drug resistance.
Detailed Description
The present invention will be further described with reference to the following examples, but the embodiments of the present invention are not limited thereto. The experimental procedures used in the following examples are all conventional procedures unless otherwise specified.
Example 1 preparation of tablets containing reduced glutathione
Taking 10 parts by weight of reducing glutathione, 50 parts by weight of starch, 20 parts by weight of microcrystalline cellulose, 10 parts by weight of sodium carboxymethylcellulose and 9 parts by weight of polyvinylpyrrolidone, mixing, performing wet granulation, adding 0.5 part by weight of magnesium stearate and 0.5 part by weight of superfine silica gel powder into dried granules, and tabletting to prepare 100 parts by weight of tablets A1 containing reducing glutathione.
Example 2 preparation of a tablet containing Salvianolic acid B
Taking 10 parts by weight of salvianolic acid B, 50 parts by weight of starch, 20 parts by weight of microcrystalline cellulose, 10 parts by weight of sodium carboxymethylcellulose and 9 parts by weight of polyvinylpyrrolidone, mixing, performing wet granulation, adding 0.5 part by weight of magnesium stearate and 0.5 part by weight of aerosil into dried granules, and tabletting to prepare 100 parts by weight of tablet A2 containing salvianolic acid B.
Example 3 preparation of tablets containing reduced glutathione and Salvianolic acid B (1:9)
Taking 1 weight part of reducing glutathione, 9 weight parts of salvianolic acid B, 50 weight parts of starch, 20 weight parts of microcrystalline cellulose, 10 weight parts of sodium carboxymethylcellulose and 9 weight parts of polyvinylpyrrolidone, mixing, performing wet granulation, adding 0.5 weight part of magnesium stearate and 0.5 weight part of superfine silica gel powder into dried granules, and tabletting to obtain 100 weight parts of tablet A3 containing reducing glutathione and salvianolic acid B (the weight ratio is 1: 9).
Example 4 preparation of tablets containing reduced glutathione and Salvianolic acid B (9:1)
Mixing 9 parts by weight of reducing glutathione, 1 part by weight of salvianolic acid B, 50 parts by weight of starch, 20 parts by weight of microcrystalline cellulose, 10 parts by weight of sodium carboxymethylcellulose and 9 parts by weight of polyvinylpyrrolidone, performing wet granulation, adding 0.5 part by weight of magnesium stearate and 0.5 part by weight of aerosil into dried granules, and tabletting to obtain 100 parts by weight of tablet A4 containing reducing glutathione and salvianolic acid B (weight ratio of 9: 1).
Example 5 preparation of tablets containing reduced glutathione and Salvianolic acid B (4:1)
Mixing 8 parts by weight of reducing glutathione, 2 parts by weight of salvianolic acid B, 50 parts by weight of starch, 20 parts by weight of microcrystalline cellulose, 10 parts by weight of sodium carboxymethylcellulose and 9 parts by weight of polyvinylpyrrolidone, performing wet granulation, adding 0.5 part by weight of magnesium stearate and 0.5 part by weight of aerosil into dried granules, and tabletting to obtain 100 parts by weight of tablet A5 containing reducing glutathione and salvianolic acid B (weight ratio of 4: 1).
Test example 1: application of composition of the invention in treating fatty liver of rat
SD male rats were randomly divided into 7 groups of 10 rats each. Basal diet was given to the blank control group, and high fat diet (basal diet 85%, lard 10%, and cholesterol 5%) was given to the model control group; high-fat feeds (base feed 75%, lard 10%, cholesterol 5% and 10% of the inventive tablets a1-a5 ground to fine powder) containing the respective active ingredients were administered to each experimental group in an amount of 20 g/day for an experimental period of 30 days. During the experiment, the general situation was observed daily: mental, appetite, hair, activity and stool, body weight was measured and recorded every seven days. At the end of the experiment, blood was collected via iliac vein, serum was separated, and triglyceride and cholesterol contents in serum were measured according to the procedure of kit instructions, and the measurement results are shown in table 1. The rat was dissected, the liver was removed, the surface tissue fluid was aspirated with filter paper, the wet weight was weighed on an electronic balance, and the surface and cross-sectional fatty changes were observed and recorded. Collecting liver tissue 0.2 g, cutting, placing in a homogenizer, adding physiological saline 2.0ml, grinding to obtain 10% liver homogenate, centrifuging at 3500rpm for 10min, collecting supernatant, and determining triglyceride and cholesterol content according to kit instruction (see Table 2).
TABLE 1 Effect of the compositions of the present invention on the plasma triglyceride and cholesterol levels in fatty liver rats
Triglyceride (mmol/L) | Cholesterol (mmol/L) | |
Blank control group | 0.61 | 1.88 |
Model control group | 1.18 | 2.69 |
Experimental group A1 | 0.81 | 1.84 |
Experimental group A2 | 0.97 | 2.06 |
Experimental group A3 | 0.79 | 1.73 |
Experimental group A4 | 0.77 | 1.67 |
Experimental group A5 | 0.70 | 1.44 |
TABLE 2 Effect of the compositions of the present invention on the triglyceride and cholesterol levels in liver homogenates of fatty liver rats
As can be seen from tables 1 and 2, after the pharmaceutical composition of the invention is taken with the reducing glutathione, the salvianolic acid B and various proportions, the contents of triglyceride and cholesterol in the plasma and the liver of the rat are reduced to different degrees compared with the content in the model control group, and the pharmaceutical composition of the invention is proved to have obvious effect on preventing and treating the fatty liver. Particularly, the combined use of the glutathione and the salvianolic acid B generates a synergistic effect, and the use amount of the medicine is reduced. Under the condition that the total amount of active ingredients is kept unchanged, the effect of the pharmaceutical composition is remarkably improved compared with that of a preparation which singly uses the glutathione and the salvianolic acid B to treat the fatty liver, wherein the pharmaceutical composition with the weight ratio of the glutathione to the salvianolic acid B being 4:1 has the most remarkable effect, and produces the excellent effect which is difficult to expect.
Claims (10)
1. A pharmaceutical composition for treating fatty liver is characterized in that the weight ratio of active ingredients glutathione to salvianolic acid B is (1:20) - (20: 1).
2. The pharmaceutical composition of claim 1, wherein the weight ratio of the active ingredients glutathione to salvianolic acid B is (1:9) - (9: 1).
3. The pharmaceutical composition of claim 2, wherein the weight ratio of the active ingredients glutathione to salvianolic acid B is 4: 1.
4. The pharmaceutical composition of any one of claims 1-3, wherein the glutathione is reduced glutathione.
5. The pharmaceutical composition according to any one of claims 1 to 3, further comprising a pharmaceutically acceptable excipient.
6. The pharmaceutical composition of claim 5, wherein the pharmaceutically acceptable excipient is selected from one or more of starch, microcrystalline cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, magnesium stearate, and aerosil.
7. The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition is in the form of tablets, capsules, injectable powder, dripping pills, and the like, preferably tablets.
8. The pharmaceutical composition of any one of claims 1 to 3, wherein 1 to 10 parts by weight of the glutathione and the salvianolic acid B are contained in 100 parts by weight of the pharmaceutical composition.
9. Use of a pharmaceutical composition according to any one of claims 1 to 8 for the manufacture of a medicament for the treatment of fatty liver.
10. The use of claim 9, wherein the fatty liver is non-alcoholic fatty liver disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110389703.8A CN112870332B (en) | 2016-04-12 | 2016-04-12 | Glutathione-containing pharmaceutical composition for treating fatty liver |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610222110.1A CN105727251B (en) | 2016-04-12 | 2016-04-12 | Pharmaceutical composition for treating fatty liver |
CN202110389703.8A CN112870332B (en) | 2016-04-12 | 2016-04-12 | Glutathione-containing pharmaceutical composition for treating fatty liver |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610222110.1A Division CN105727251B (en) | 2016-04-12 | 2016-04-12 | Pharmaceutical composition for treating fatty liver |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112870332A true CN112870332A (en) | 2021-06-01 |
CN112870332B CN112870332B (en) | 2023-11-07 |
Family
ID=56253072
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610222110.1A Active CN105727251B (en) | 2016-04-12 | 2016-04-12 | Pharmaceutical composition for treating fatty liver |
CN202110389703.8A Active CN112870332B (en) | 2016-04-12 | 2016-04-12 | Glutathione-containing pharmaceutical composition for treating fatty liver |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610222110.1A Active CN105727251B (en) | 2016-04-12 | 2016-04-12 | Pharmaceutical composition for treating fatty liver |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN105727251B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107812182B (en) * | 2017-11-27 | 2020-03-06 | 中国药科大学 | Application of neuraminidase and inhibitor in preparation of medicine for inhibiting hepatic gluconeogenesis |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101450051A (en) * | 2007-12-07 | 2009-06-10 | 苑立超 | Monomer salvianolic acid B injection and preparation method thereof |
WO2009076869A1 (en) * | 2007-12-07 | 2009-06-25 | Lichao Yuan | Salvianolic acid of high purity, preparation method and use thereof |
CN102139084A (en) * | 2011-04-01 | 2011-08-03 | 南京中医药大学 | Chinese medicinal composition for treating fatty liver and preparation method and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103933541B (en) * | 2014-05-12 | 2016-01-20 | 潘宏涛 | A kind of glutathion anti-cancer composition |
-
2016
- 2016-04-12 CN CN201610222110.1A patent/CN105727251B/en active Active
- 2016-04-12 CN CN202110389703.8A patent/CN112870332B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101450051A (en) * | 2007-12-07 | 2009-06-10 | 苑立超 | Monomer salvianolic acid B injection and preparation method thereof |
WO2009076869A1 (en) * | 2007-12-07 | 2009-06-25 | Lichao Yuan | Salvianolic acid of high purity, preparation method and use thereof |
CN102139084A (en) * | 2011-04-01 | 2011-08-03 | 南京中医药大学 | Chinese medicinal composition for treating fatty liver and preparation method and application thereof |
Non-Patent Citations (4)
Title |
---|
何明;: "丹参注射液、还原型谷胱甘肽联合治疗酒精性肝病50例", 中医研究, no. 12, pages 187 - 29 * |
刘建国;丁艳蕊;杨胜兰;黄芳;: "丹酚酸B对实验性肝纤维化大鼠肝组织CD14表达的影响", 中国中西医结合杂志, no. 04, pages 547 - 551 * |
徐晨光;闫洁;陈蓝羽;李娟梅;吕文良;: "丹参有效成分抗肝纤维化作用机制的研究进展", 环球中医药, no. 04, pages 305 - 308 * |
黄妙珍;孙丽伟;付珍春;任晓华;来德利;: "丹参注射液联合谷胱甘肽液治疗对脂肪肝大鼠脂质损伤的保护作用", 中国中西医结合消化杂志, no. 06, pages 386 - 389 * |
Also Published As
Publication number | Publication date |
---|---|
CN105727251A (en) | 2016-07-06 |
CN105727251B (en) | 2021-06-08 |
CN112870332B (en) | 2023-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Londhe et al. | Role of garlic (Allium sativum) in various diseases: An overview | |
Rathore et al. | Indian herbal medicines: Possible potent therapeutic agents for rheumatoid arthritis | |
WO2009097512A1 (en) | Herbal pharmaceutical compositions to treat inflammation and inflammation associated conditions and diseases | |
CN101612362B (en) | Complex preparation for regulating lipid and preventing and curing heart cerebrovascular diseases and preparation method thereof | |
CN102302555A (en) | Chinese medicinal extract for treating urarthritis, as well as preparation method and application thereof | |
Li et al. | Effects of taraxasterol against ethanol and high-fat diet-induced liver injury by regulating TLR4/MyD88/NF-κB and Nrf2/HO-1 signaling pathways | |
WO2018099216A1 (en) | Traditional chinese medicine composition for treating atherosclerosis-caused hypertension and application thereof | |
CN105232525A (en) | Hypolipidemic drug combination and application thereof | |
Roghani‐Shahraki et al. | Herbal therapy as a promising approach for regulation on lipid profiles: A review of molecular aspects | |
EP3406258B1 (en) | Medicament for use in treating gout | |
CN110075216B (en) | Food composition with auxiliary blood fat reducing, weight losing and liver protecting effects and preparation method, preparation and application thereof | |
CN105727251B (en) | Pharmaceutical composition for treating fatty liver | |
CN101897925B (en) | Medicinal composition for treating metabolic syndrome | |
CN105582003A (en) | Application of methyl ferulic acid in preparation of medicine for preventing and treating alcoholic liver disease | |
CN112439018A (en) | Composition with weight-losing and lipid-lowering functions as well as preparation method and application thereof | |
CN1679639A (en) | Oral soft capsule of medicinal preparation from blood-activating Chinese medicine pseudo-ginseng and leech extract | |
Lee et al. | Anti-obesity effect of Aster yomena ethanol extract in high fat diet-induced obese mice | |
KR20090095740A (en) | The healthy and funtional foods for the improvements and prevention of the arthritis symptoms with anti-inflammatory and anti-nociceptive | |
CN106074662A (en) | A kind of Rhizoma Curcumae Longae compositions with effects of relieving alcoholism and protecting liver | |
KR20180101460A (en) | Uses of Sisotanke Tubulosa Extract and Isoquateroside in the Protection of Muscle | |
Zhang et al. | Bioactive Components of Chinese Herbal Medicines in the Treatment of Glucose and Lipid Metabolism Disorders: Evidence and Potential Mechanisms | |
Mitra | Pharmacology and biochemistry behind the use of natural herbs to control arthritis–A review | |
CN1215876C (en) | Antigout medicinal composition and its preparing method | |
CN105943583B (en) | Sweet wormwood herb and red yeast rice composition and application thereof | |
Ibrahim | Anti-Obesity Effects of Arum maculatum, Nasturtium officinale Plant Extracts and Exercise in High Fat Diet-Induced Obese Rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |